Sort   by:  
 Page size 
TranscriptomicsExpression data of A375 melanoma cells after DMSO or MLN4924 treatment from 1 hour to 24 hour
Microarrays were used to determine the change in gene expression of genes involved in the CDT1/NAE pathway A375 cells were grown and then incubated in the presence of either DMSO as control or 650nM MLN4924. Cells were treated for 1, 2, 4, 8, and 24 hours. RNA extraction and hybridization on Affymet...
ORGANISM(S): Homo sapiens 
2011-07-09 | E-GEOD-30531 | biostudies-arrayexpress
TranscriptomicsA375 melanoma cells treated with leflunomide 25uM
Human A375 melanoma cells were treated with leflunomide 25uM for 3 days, then RNA harvested 6 arrays
ORGANISM(S): Homo sapiens 
2011-03-30 | E-GEOD-24526 | biostudies-arrayexpress
ProteomicsUntreated A375 cells vs BRAFi/MEKi-treated A375 cells
Quantitative proteomic analysis in untreated A375 cells and BRAFi/MEKi-treated A375 cells
ORGANISM(S): Homo sapiens (Human) 
2026-06-18 | PXD068007 | Pride
Drug-tolerant cells Targeted therapy A375 
TranscriptomicsGene expression profile in A375 melanoma cells after 45 functionally important molecules were knocked down using siRNA
Affymetrix microarray data were generated from A375 melanoma cells treated in vitro with siRNAs against 45 transcription factors and signalling molecules. 45 functionally important molecules were knocked down in A375 melanoma cells by siRNA. Then the gene expression profiles of these A375 cells, alo...
ORGANISM(S): Homo sapiens 
2012-03-15 | E-GEOD-31534 | biostudies-arrayexpress
TranscriptomicsTranscriptome data from human malanoma A375 cells stably expressing MAP4K5 shRNA.
MAP4K5 is serine/threonine protein kinase similar to yeast SPS1/STE20 kinase. MAP4K5 activates JNK in mammalian cells, which suggests a role in stress response. MAP4K5 is involved in immune functions. We used microarray to investigate genome-wide transcriptional change from MAP4K5 knockdown in A375 ...
ORGANISM(S): Homo sapiens 
2014-09-18 | E-GEOD-61497 | biostudies-arrayexpress
TranscriptomicsAnalysis of A375 and A375 clones that acquired resistance to GSK2118436 after treatment with GSK2118436 (GSK436), GSK1120212 (GSK212), or the combination of GSK2118436 and GSK1120212 for 24 hour
In an effort to understand the mechanisms of acquired resistance to BRAF inhibitors, we isolated clones that acquired resistance to the BRAF inhibitor GSK2118436 derived from the A375 BRAF V600E mutant melanoma cell line. This resistance clones acquired mutations in NRAS and MEK1. One clones, 16R6-4...
ORGANISM(S): Homo sapiens 
2012-02-01 | E-GEOD-35230 | biostudies-arrayexpress
TranscriptomicsExpression data from BRAFV600E A375 melanoma cells treated with vehicle or vemurafenib
Vemurafenib is a BRAF inhibitor with specificity for the most common BRAF mutant encountered in melanomas (BRAFV600E). Vemurafenib suppresses the proliferation of BRAF mutant human melanoma cells by suppressing downstream activation of the MEK/ERK mitogen activated protein kinases. We used microarra...
ORGANISM(S): Homo sapiens 
2014-05-20 | E-GEOD-42872 | biostudies-arrayexpress
Genomicsgene-expression profiling between UBE2S knock down A375 cells and control A375 cells
gene-expression profiling between UBE2S knock down A375 cells and control A375 cells
PRJNA476507 | ENA
TranscriptomicsExpression data of A375 melanoma cells after DMSO or MLN4924 +/- Nutlin treatment for 26 hours
Microarrays were used to determine the change in gene expression of genes involved in the p53 pathway after siRNA knock down of p53, CDT1 or BRCA1 A375 cells were grown, transfected with siRNA, incubated for 48hrs, then incubated for another 26hrs in the presence of either 0.065% DMSO as control, 65...
ORGANISM(S): Homo sapiens 
2012-07-03 | E-GEOD-39091 | biostudies-arrayexpress
GenomicsHomo sapiens strain:A375
CRISPR/Cas9 drug uptake screen in A375
PRJNA416669 | ENA
Sort   by:  
 Page size